New drug cocktail aims to control relapsed blood cancer
NCT ID NCT07479979
First seen Mar 21, 2026 · Last updated May 22, 2026 · Updated 11 times
Summary
This study tests a combination of four drugs (selinexor, carfilzomib, isatuximab, and dexamethasone) in people whose multiple myeloma has returned or stopped responding to treatment. The goal is to see if the combination is safe and helps control the cancer. About 62 adults who have had at least one prior therapy will participate. This is not a cure; patients will need ongoing treatment to manage the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Wisconsin
RECRUITINGMadison, Wisconsin, 53705, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.